The role of lipopolysaccharide-binding protein in innate immunity: A revisit and its relevance to oral/periodontal health

Journal of Periodontal Research

Volumn 49, Issue 1, 2014, Pages 1-9

  Ding, P H ^a   Jin, L J ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Biomarker; Gene polymorphism; Innate immunology; Lipopolysaccharide binding protein; Periodontal health; Review

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; CARRIER PROTEIN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN;

GENETIC POLYMORPHISM; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; PERIODONTAL DISEASES; PERIODONTIUM;

ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; CARRIER PROTEINS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; LIPOPOLYSACCHARIDES; MEMBRANE GLYCOPROTEINS; PERIODONTAL DISEASES; PERIODONTIUM; POLYMORPHISM, GENETIC;

EID: 84891837084     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/jre.12081     Document Type: Review

References (105)

1. Tobias PS, Soldau K, Ulevitch RJ. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med 1986;164:777-793.
2. Schumann RR. Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule. Biochem Soc Trans 2011;39:989-993.
3. Schumann RR, Leong SR, Flaggs GW et al. Structure and function of lipopolysaccharide binding protein. Science 1990;249:1429-1431.
4. Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 1997; 276: 1861-1864.
5. Beamer LJ, Carroll SF, Eisenberg D. The three-dimensional structure of human bactericidal/permeability-increasing protein: implications for understanding protein-lipopolysaccharide interactions. Biochem Pharmacol 1999;57:225-229.
6. Gazzano-Santoro H, Meszaros K, Birr C et al. Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect Immun 1994;62:1185-1191.
7. Iovine NM, Elsbach P, Weiss J. An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains. Proc Natl Acad Sci USA 1997;94:10973-10978.
8. Froon AHM, Dentener MA, Greve JWM, Ramsay G, Buurman WA. Lipopolysaccharide toxicity-regulating proteins in bacteremia. J Infect Dis 1995;171:1250-1257.
9. Schumann RR, Zweigner J. A novel acute-phase marker: lipopolysaccharide binding protein (LBP). Clin Chem Lab Med 1999;37:271-274.
10. Myc A, Buck J, Gonin J, Reynolds B, Hammerling U, Emanuel D. The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome. Clin Diagn Lab Immunol 1997;4:113-116.
11. Opal SM, Scannon PJ, Vincent JL et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999;180:1584-1589.
12. Blairon L, Wittebole X, Laterre PF. Lipopolysaccharide-binding protein serum levels in patients with severe sepsis due to gram-positive and fungal infections. J Infect Dis 2003;187:287-291.
13. Pavcnik-Arnol M, Hojker S, Derganc M. Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin-6, and C-reactive protein. Intensive Care Med 2004;30:1454-1460.
14. Gaini S, Koldkjaer OG, Pedersen C, Pedersen SS. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care 2006;10:R53.
15. Watkin RW, Harper LV, Vernallis AB et al. Pro-inflammatory cytokines IL6, TNF-alpha, IL1beta, procalcitonin, lipopolysaccharide binding protein and C-reactive protein in infective endocarditis. J Infect 2007;55:220-225.
16. Sakr Y, Burgett U, Nacul FE, Reinhart K, Brunkhorst F. Lipopolysaccharide binding protein in a surgical intensive care unit: a marker of sepsis? Crit Care Med 2008;36:2014-2022.
17. Mierzchala M, Krzystek-Korpacka M, Gamian A, Durek G. Quantitative indices of dynamics in concentrations of lipopolysaccharide-binding protein (LBP) as prognostic factors in severe sepsis/septic shock patients - comparison with CRP and procalcitonin. Clin Biochem 2011;44:357-363.
18. Villar J, Perez-Mendez L, Espinosa E et al. Serum lipopolysaccharide binding protein levels predict severity of lung injury and mortality in patients with severe sepsis. PLoS ONE 2009;4:e6818.
19. Prucha M, Herold I, Zazula R et al. Significance of lipopolysaccharide-binding protein (an acute phase protein) in monitoring critically ill patients. Crit Care 2003;7:R154-159.
20. Gaini S, Koldkjaer OG, Moller HJ, Pedersen C, Pedersen SS. A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study. Crit Care 2007;11:R76.
21. Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med 2011;24:12-14.
22. Anisimova N, Gromova EG, Kuznetsova LS, Kiselevskii MV. Prognostic value of lipopolysaccharide and lipopolysaccharide-binding protein serum levels in cancer patients with sepsis. Zh Mikrobiol Epidemiol Immunobiol 2011; 82-84.
23. Vollmer T, Piper C, Kleesiek K, Dreier J. Lipopolysaccharide-binding protein: a new biomarker for infectious endocarditis? Clin Chem 2009;55:295-304.
24. Sablotzki A, Borgermann J, Baulig W et al. Lipopolysaccharide-binding protein (LBP) and markers of acute-phase response in patients with multiple organ dysfunction syndrome (MODS) following open heart surgery. Thorac Cardiovasc Surg 2001;49:273-278.
25. Lepper PM, Schumann C, Triantafilou K et al. Association of lipopolysaccharide-binding protein and coronary artery disease in men. J Am Coll Cardiol 2007;50:25-31.
26. Lepper PM, Kleber ME, Grammer TB et al. Lipopolysaccharide-binding protein (LBP) is associated with total and cardiovascular mortality in individuals with or without stable coronary artery disease - Results from the Ludwigshafen Risk and Cardiovascular Health Study (LURIC). Atherosclerosis 2011;219:291-297.
27. Erwin PJ, Lewis H, Dolan S et al. Lipopolysaccharide binding protein in acute pancreatitis. Crit Care Med 2000;28:104-109.
28. Kaden J, Zwerenz P, Lambrecht HG, Dostatni R. Lipopolysaccharide-binding protein as a new and reliable infection marker after kidney transplantation. Transpl Int 2002;15:163-172.
29. Albillos A, de la Hera A, Gonzalez M et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003;37:208-217.
30. Albillos A. de-La-Hera A, Alvarez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 2004;363:1608-1610.
31. Kleine TO, Zwerenz P, Zofel P, Shiratori K. New and old diagnostic markers of meningitis in cerebrospinal fluid (CSF). Brain Res Bull 2003;61:287-297.
32. Masia M, Gutierrez F, Llorca B et al. Serum concentrations of lipopolysaccharide-binding protein as a biochemical marker to differentiate microbial etiology in patients with community-acquired pneumonia. Clin Chem 2004;50:1661-1664.
33. Cunningham SC, Malone DL, Bochicchio GV et al. Serum lipopolysaccharide-binding protein concentrations in trauma victims. Surg Infect (Larchmt) 2006;7:251-261.
34. Orlikowsky TW, Trug C, Neunhoeffer F, Deperschmidt M, Eichner M, Poets CF. Lipopolysaccharide-binding protein in noninfected neonates and those with suspected early-onset bacterial infection. J Perinatol 2006;26:115-119.
35. Ubenauf KM, Krueger M, Henneke P, Berner R. Lipopolysaccharide binding protein is a potential marker for invasive bacterial infections in children. Pediatr Infect Dis J 2007;26:159-162.
36. Chen FC, Sarioglu N, Buscher U, Dudenhausen JW. Lipopolysaccharide binding protein in the early diagnosis of intraamniotic infection of pregnant women with premature rupture of the membranes. J Perinat Med 2009;37:135-139.
37. Elsing C, Ernst S, Kayali N, Stremmel W, Harenberg S. Lipopolysaccharide binding protein, interleukin-6 and C-reactive protein in acute gastrointestinal infections: value as biomarkers to reduce unnecessary antibiotic therapy. Infection 2011;39:327-331.
38. Lakatos PL, Kiss LS, Palatka K et al. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. Inflamm Bowel Dis 2011;17:767-777.
39. Moreno-Navarrete JM, Ortega F, Serino M et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes (Lond) 2011; 36:1442-1449.
40. Lin X, Sun LA, Yu ZJ et al. A Marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care 2010;33:1925-1932.
41. Tobias PS, Soldau K, Ulevitch RJ. Identification of a lipid-a binding-site in the acute phase reactant lipopolysaccharide binding-protein. J Biol Chem 1989;264:10867-10871.
42. Taylor AH, Heavner G, Nedelman M et al. Lipopolysaccharide (LPS) neutralizing peptides reveal a lipid a binding-site of LPS binding-protein. J Biol Chem 1995;270:17934-17938.
43. Lamping N, Hoess A, Yu B et al. Effects of site-directed mutagenesis of basic residues (Arg 94, Lys 95, Lys 99) of lipopolysaccharide (LPS)-binding protein on binding and transfer of LPS and subsequent immune cell activation. J Immunol 1996;157:4648-4656.
44. Martin TR, Mathison JC, Tobias PS et al. Lipopolysaccharide binding-protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide - Implications for cytokine production in normal and injured Lungs. J Clin Invest 1992;90:2209-2219.
45. Wright SD, Tobias PS, Ulevitch RJ, Ramos RA. Lipopolysaccharide (LPS) binding-protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages. J Exp Med 1989;170:1231-1241.
46. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249:1431-1433.
47. Yu B, Wright SD. Catalytic properties of lipopolysaccharide (LPS) binding protein - Transfer of LPS to soluble CD14. J Biol Chem 1996;271:4100-4105.
48. Amar S, Oyaisu K, Li L, Van Dyke T. Moesin: a potential LPS receptor on human monocytes. J Endotoxin Res 2001;7:281-286.
49. Iontcheva I, Amar S, Zawawi KH, Kantarci A, Van Dyke TE. Role for moesin in lipopolysaccharide-stimulated signal transduction. Infect Immun 2004;72:2312-2320.
50. Zawawi KH, Kantarci A, Schulze-Spate U et al. Moesin-induced signaling in response to lipopolysaccharide in macrophages. J Periodontal Res 2010;45:589-601.
51. Tobias PS, Soldau K, Gegner JA, Mintz D, Ulevitch RJ. Lipopolysaccharide-binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem 1995;270:10482-10488.
52. Gegner JA, Ulevitch RJ, Tobias PS. Lipopolysaccharide (LPS) signal-transduction and clearance - dual roles for LPS binding-protein and membrane CD14. J Biol Chem 1995;270:5320-5325.
53. Fan MH, Klein RD, Steinstraesser L et al. An essential role for lipopolysaccharide-binding protein in pulmonary innate immune responses. Shock 2002;18:248-254.
54. Ahren IL, Bjartell A, Egesten A, Riesbeck K. Lipopolysaccharide-binding protein increases toll-like receptor 4-dependent activation by nontypeable Haemophilus influenzae. J Infect Dis 2001;184:926-930.
55. Weber JR, Freyer D, Alexander C et al. Recognition of pneumococcal peptidoglycan: an expanded, pivotal role for LPS binding protein. Immunity 2003;19:269-279.
56. Schroder NW, Morath S, Alexander C et al. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 2003;278:15587-15594.
57. Schroder NWJ, Opitz B, Lamping N et al. Involvement of lipopolysaccharide binding protein, CD14, and toll-like receptors in the initiation of innate immune responses by Treponema glycolipids. J Immunol 2000;165:2683-2693.
58. Schroder NWJ, Heine H, Alexander C et al. Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses. J Immunol 2004;173:2683-2691.
59. Gutsmann T, Muller M, Carroll SF, MacKenzie RC, Wiese A, Seydel U. Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun 2001;69:6942-6950.
60. Dentener MA, Von Asmuth EJ, Francot GJ, Marra MN, Buurman WA. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes. Competition for binding to lipopolysaccharide. J Immunol 1993;151:4258-4265.
61. Heumann D, Gallay P, Barras C et al. Control of lipopolysaccharide (LPS) binding and LPS-induced tumor-necrosis-factor secretion in human peripheral-blood monocytes. J Immunol 1992;148:3505-3512.
62. Gallay P, Heumann D, Leroy D, Barras C, Glauser MP. Lipopolysaccharide-binding protein as a major plasma-protein responsible for endotoxemic shock. Proc Natl Acad Sci USA 1993;90:9935-9938.
63. Wurfel MM, Monks BG, Ingalls RR et al. Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med 1997;186:2051-2056.
64. Lamping N, Dettmer R, Schroder NW et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest 1998;101:2065-2071.
65. Jack RS, Fan XL, Bernheiden M et al. Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection. Nature 1997;389:742-745.
66. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994;180:1025-1035.
67. Gioannini TL, Teghanemt A, Zarember KA, Weiss JP. Regulation of interactions of endotoxin with host cells. J Endotoxin Res 2003;9:401-408.
68. Thompson PA, Tobias PS, Viriyakosol S, Kirkland TN, Kitchens RL. Lipopolysaccharide (LPS)-binding protein inhibits responses to cell-bound LPS. J Biol Chem 2003;278:28367-28371.
69. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 2005;11:225-229.
70. Muller M, Scheel O, Lindner B, Gutsmann T, Seydel U. The role of membrane-bound LBP, endotoxin aggregates, and the MaxiK channel in LPS-induced cell activation. J Endotoxin Res 2003;9:181-186.
71. Mueller M, Brandenburg K, Dedrick R, Schromm AB, Seydel U. Phospholipids inhibit lipopolysaccharide (LPS)-induced cell activation: a role for LPS-binding protein. J Immunol 2005;174:1091-1096.
72. Roes S, Mumm F, Seydel U, Gutsmann T. Localization of the lipopolysaccharide-binding protein in phospholipid membranes by atomic force microscopy. J Biol Chem 2006;281:2757-2763.
73. Hubacek JA, Buchler C, Aslanidis C, Schmitz G. The genomic organization of the genes for human lipopolysaccharide binding protein (LBP) and bactericidal permeability increasing protein (BPI) is highly conserved. Biochem Biophys Res Commun 1997;236:427-430.
74. Hubacek JA, Stuber F, Frohlich D et al. Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med 2001;29:557-561.
75. Barber RC, O'Keefe GE. Characterization of a single nucleotide polymorphism in the lipopolysaccharide binding protein and its association with sepsis. Am J Respir Crit Care Med 2003;167:1316-1320.
76. Hubacek JA, Pitha J, Skodova Z et al. Polymorphisms in the lipopolysaccharide-binding protein and bactericidal/permeability-increasing protein in patients with myocardial infarction. Clin Chem Lab Med 2002;40:1097-1100.
77. Vollmer T, Kleesiek K, Dreier J. Lipopolysaccharide-binding protein (LBP) gene polymorphisms: rapid genotyping by real-time PCR and association with infective endocarditis. Clin Biochem 2009;42:1413-1419.
78. Chien JW, Boeckh M, Hansen JA, Clark JG. Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008;14:106-106.
79. Vreugdenhil AC, Dentener MA, Snoek AM, Greve JW, Buurman WA. Lipopolysaccharide binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response. J Immunol 1999;163:2792-2798.
80. Vreugdenhil AC, Snoek AM, Greve JW, Buurman WA. Lipopolysaccharide-binding protein is vectorially secreted and transported by cultured intestinal epithelial cells and is present in the intestinal mucus of mice. J Immunol 2000;165:4561-4566.
81. Dentener MA, Vreugdenhil AC, Hoet PH et al. Production of the acute-phase protein lipopolysaccharide-binding protein by respiratory type II epithelial cells: implications for local defense to bacterial endotoxins. Am J Respir Cell Mol Biol 2000;23:146-153.
82. Su GL, Freeswick PD, Geller DA et al. Molecular-cloning, characterization, and tissue distribution of rat lipopolysaccharide-binding protein - evidence for extrahepatic expression. J Immunol 1994;153:743-752.
83. Jin LJ. An update on innate defense molecules of human gingiva. Periodontol 2000 2011;56:125-142.
84. Ren L, Jin LJ, Leung WK. Local expression of lipopolysaccharide-binding protein in human gingival tissues. J Periodontal Res 2004;39:242-248.
85. Ding PH, Wang CY, Darveau RP, Jin LJ. Porphyromonas gingivalis LPS stimulates the expression of LPS-binding protein in human oral keratinocytes in vitro. Innate Immun 2013;19:66-75.
86. Lu Q, Jin LJ. Human gingiva is another site of C-reactive protein formation. J Clin Periodontol 2010;37:789-796.
87. Hosokawa I, Hosokawa Y, Komatsuzawa H et al. Innate immune peptide LL-37 displays distinct expression pattern from beta-defensins in inflamed gingival tissue. Clin Exp Immunol 2006;146:218-225.
88. Lu Q, Darveau RP, Samaranayake LP, Wang CY, Jin LJ. Differential modulation of human β-defensins expression in human gingival epithelia by Porphyromonas gingivalis lipopolysaccharide with tetra- and penta-acylated lipid A structures. Innate Immun 2009;15:325-335.
89. Heumann D, Roger T. Initial responses to endotoxins and Gram-negative bacteria. Clin Chim Acta 2002;323:59-72.
90. Wang PL, Ohura K. Porphyromonas gingivalis lipopolysaccharide signaling in gingival fibroblasts-CD14 and toll-like receptors. Crit Rev Oral Biol Med 2002;13:132-142.
91. Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003;3:169-176.
92. Ren L, Leung WK, Darveau RP, Jin LJ. The expression profile of lipopolysaccharide-binding protein, membrane-bound CD14, and toll-like receptors 2 and 4 in chronic periodontitis. J Periodontol 2005;76:1950-1959.
93. Alexander MB, Damoulis PD. The role of cytokines in the pathogenesis of periodontal disease. Curr Opin Periodontol 1994; 1: 39-53.
94. Seymour GJ, Gemmell E. Cytokines in periodontal disease: where to from here? Acta Odontol Scand 2001;59:167-173.
95. Malkowska A, Kasprzak A, Stopa J. Proinflammatory cytokines in pathogenesis of periodontal disease. Pol Merkur Lekarski 2006;20:93-98.
96. Ren L, Jiang ZQ, Fu Y, Leung WK, Jin LJ. The interplay of lipopolysaccharide-binding protein and cytokines in periodontal health and disease. J Clin Periodontol 2009;36:619-626.
97. Ren L, Leung WK, Loo TW, Jin LJ. Lipopolysaccharide-binding protein down-regulates the expression of interleukin-6 by human gingival fibroblast. J Periodontal Res 2005;40:407-416.
98. Hajishengallis G, Liang S, Payne MA et al. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. Cell Host Microbe 2011;10:497-506.
99. Darveau RP. The oral microbial consortium's interaction with the periodontal innate defense system. DNA Cell Biol 2009;28:389-395.
100. Al-Qutub MN, Braham PH, Karimi-Naser LM, Liu X, Genco CA, Darveau RP. Hemin-dependent modulation of the lipid A structure of Porphyromonas gingivalis lipopolysaccharide. Infect Immun 2006;74:4474-4485.
101. Curtis MA, Percival RS, Devine D et al. Temperature-dependent modulation of Porphyromonas gingivalis lipid A structure and interaction with the innate host defenses. Infect Immun 2011;79:1187-1193.
102. Darveau RP, Pham TT, Lemley K et al. Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both toll-like receptors 2 and 4. Infect Immun 2004;72:5041-5051.
103. Herath TD, Wang Y, Seneviratne CJ et al. Porphyromonas gingivalis lipopolysaccharide lipid A heterogeneity differentially modulates the expression of IL-6 and IL-8 in human gingival fibroblasts. J Clin Periodontol 2011;38:694-701.
104. Reife RA, Coats SR, Al-Qutub M et al. Porphyromonas gingivalis lipopolysaccharide lipid A heterogeneity: differential activities of tetra- and penta-acylated lipid A structures on E-selectin expression and TLR4 recognition. Cell Microbiol 2006;8:857-868.
105. Ding PH, Darveau RP, Wang CY, Jin LJ. Nuclear factor-κB and p38 mitogen-activated protein kinase signaling pathways are critically involved in Porphyromonas gingivalis lipopolysaccharide induction of lipopolysaccharide-binding protein expression in human oral keratinocytes. Mol Oral Microbiol 2013;28:129-141.